Omalizumab (Tianchen Biomedical)

奥马珠单抗（天辰生物）

Report date: 2025/06/23 13:36:23

Base Information

Drug NameOmalizumab (Tianchen Biomedical)
Drug Alias Name人源化抗人 IgE 单克隆抗体注射液人源化抗人 IgE 单克隆抗体（天辰生物）
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionImmunoglobulin E inhibitorsImmunosuppressants
TargetsImmunoglobulin E
Therapy Area/IndicationsChronic Urticaria
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesLongbio Pharma (Suzhou) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesLongbio Pharma (Suzhou) Co Ltd
Inactive CompaniesN/A
Active IndicationsChronic Urticaria
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A